# ARC-7 (NCT04262856)

> Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: domvanalimab plus zimberelimab; domvanalimab plus zimberelimab plus etrumadenant; zimberelimab
- Indication: front-line PD-L1 positive non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04262856
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Arcus Biosciences, Inc.
- Conditions: Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancer; Lung Cancer
- Interventions: Domvanalimab; Etrumadenant; Zimberelimab
- Enrollment: 151
- Primary outcome: Objective response rate (ORR)
- Primary outcome: Progression-free survival (PFS)

## Indexed commentary on ARC-7 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 9 posts on X
- 3 podcast episodes
- 1 YouTube video

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=arc-7-nct04262856

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04262856", "email": "<work email>"}; the inbox owner confirms by the emailed link.